Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly and Co (NYSE:LLY) is making headlines with its $15 billion share buyback plan and a 15% dividend boost.
禮來（紐交所：LLY）因其150億美元的股票回購計劃和15%的分紅提升而成爲頭條新聞。
Yet, as the Indianapolis-based pharma giant enjoys the success of blockbuster drugs like Mounjaro and Zepbound, its stock is sending mixed technical signals ahead of its next move.
儘管這家總部位於印第安納波利斯的製藥巨頭因其重磅藥物如Mounjaro和Zepbound而享受成功，但其股票在下一步之前發出了混合的技術信號。
Eli Lilly Stock Chart: Bulls & Bears Face Off
禮來的股票圖表：看多與看空的對抗
Chart created using Benzinga Pro
圖表使用Benzinga Pro創建
Read Also: As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
另請參閱：隨着禮來股票今年迄今上漲超過35%，製藥商宣佈150億美元的股票回購計劃，並提升15%的股息。
Eli Lilly's stock, at $800.13, sits in a precarious zone with its short-term technicals painting a mixed picture:
禮來的股票目前爲800.13美元，處於一個微妙的區域，其短期技術圖顯示出混合的跡象：
- Bearish Signals Dominate: The stock trades below its eight-day SMA ($811.79), 50-day SMA ($841.23) and 200-day SMA ($838.29), flashing several bearish indicators. In fact, the 50-day SMA and the 200-day SMA appear to be moving towards making a Death Cross. The Moving Average Convergence Divergence (MACD) reading of a negative 5.12 also suggests further bearish momentum.
- A Glimmer of Bullish Hope: The 20-day SMA at $784.85 positions the stock as bullish over this timeframe, indicating potential short-term support.
- Momentum Concerns: With a Relative Strength Index (RSI) of 47.31, LLY stock hovers in neutral territory, leaving plenty of room for further downside or a recovery rally.
- 消極信號佔主導：該股票交易價格低於其八日SMA（811.79美元）、50日SMA（841.23美元）和200日SMA（838.29美元），發出多個消極指標。實際上，50日SMA和200日SMA似乎正趨向形成死亡交叉。移動平均收斂發散（MACD）讀數爲負5.12，也表明進一步的消極動能。
- 看好希望的曙光：20日簡單移動平均線爲784.85美元，使股票在此時間段內呈現看好，暗示潛在的短期壓力位。
- 動能擔憂：相對強弱指數（RSI）爲47.31，LLY股票徘徊在中立區域，留有更多下行或復甦反彈的空間。
Growth Meets Investor Skepticism
增長與投資者懷疑主義的相遇
Despite the lukewarm chart signals, Eli Lilly's fundamentals remain strong, driven by surging demand for its diabetes and obesity treatments. CFO Lucas Montarce emphasized the company's commitment to growth through new launches, expanded manufacturing capacity, and ongoing R&D.
儘管圖表信號平平，禮來的基本面依然強勁，受益於對糖尿病和肥胖症治療需求的激增。首席財務官盧卡斯·蒙塔爾斯強調，公司致力於通過新產品發佈、擴大製造能力和持續的研發來實現增長。
While investors welcomed the buyback and dividend news, pushing shares up in after-hours trading on Monday, LLY's technical outlook suggests it may struggle to maintain upward momentum in the short term.
雖然投資者對股票回購和分紅消息表示歡迎，使得週一盤後交易中股票上漲，但LLY的技術前景表明，短期內可能難以維持上漲動能。
As the stock navigates this delicate balance, Wall Street will be watching whether Eli Lilly's buyback spree can tip the scales in favor of the bulls.
在股票應對這種微妙平衡時，華爾街將關注禮來的股票回購風潮是否能夠傾向於多頭。
- What's Going On With Eli Lilly Stock On Tuesday?
- 週二Eli Lilly股票發生了什麼？
Image: Shutterstock
圖片：Shutterstock
譯文內容由第三人軟體翻譯。